Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients
CompletedOBSERVATIONAL
Enrollment
34
Participants
Timeline
Start Date
March 1, 2018
Primary Completion Date
October 28, 2020
Study Completion Date
October 28, 2020
Conditions
Acute Myeloid Leukemia
Trial Locations (1)
27599
UNC Lineberger, Chapel Hill
All Listed Sponsors
lead
UNC Lineberger Comprehensive Cancer Center
OTHER
NCT03488862 - Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients | Biotech Hunter | Biotech Hunter